Prismocitrate 18
Phase 3Terminated 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Regional Citrate Anticoagulation (RCA)
Conditions
Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury
Trial Timeline
Sep 27, 2016 → May 12, 2018
NCT ID
NCT02860130About Prismocitrate 18
Prismocitrate 18 is a phase 3 stage product being developed by Baxter for Regional Citrate Anticoagulation (RCA). The current trial status is terminated. This product is registered under clinical trial identifier NCT02860130. Target conditions include Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05399537 | Phase 3 | Recruiting |
| NCT02860130 | Phase 3 | Terminated |
Competing Products
6 competing products in Regional Citrate Anticoagulation (RCA)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD2936 | AstraZeneca | Phase 2 | 52 |
| Zoledronic acid + Placebo | Novartis | Phase 2 | 52 |
| Ribociclib + Fulvestrant + Anastrozole + Letrozole + Exemestane | Novartis | Phase 2 | 52 |
| Pregabalin | Pfizer | Pre-clinical | 22 |
| Prismocitrate 18 | Baxter | Phase 3 | 74 |
| AXS-02 (oral zoledronate) + Placebo | Axsome Therapeutics | Phase 3 | 74 |